The trial involves a particular formulation of ibuprofen, which researchers said had been shown to be more effective than standard ibuprofen for treating severe acute respiratory distress syndrome, a complication of COVID-19.

"There is some evidence to support the claim, but there's just as much evidence to not support it," the Canadian Pharmacists Association says.